First Use of Tamoxifen in an HIV Patient with Encapsulating Peritoneal Sclerosis
- 20 Downloads
Encapsulating peritoneal sclerosis (EPS) is a rare but serious life-threatening complication in peritoneal dialysis patients. At present, there is no evidence-based standard therapy for EPS. Tamoxifen has been used and shown good results in non-HIV peritoneal dialysis patients with EPS. We report a case of a patient with HIV treated with antiretroviral therapy (zidovudine, lamivudine and saquinavir) for several years. He had end-stage renal disease and was treated with continuous ambulatory peritoneal dialysis (CAPD). After 11 years on CAPD, he developed EPS and was treated successfully with tamoxifen in combination with corticosteroids. No adverse effects were observed and no changes were noted in CD4 counts or HIV viral load during this therapy. These findings suggest that tamoxifen can be safely given to HIV patients with peritoneal dialysis-related EPS. Nevertheless, caution is required as tamoxifen could interact with certain antiretroviral agents.
KeywordsTamoxifen Lamivudine Zidovudine Therapeutic Drug Monitoring Saquinavir
No sources of funding were used to assist in the preparation of this report. The authors have no conflicts of interest that are directly relevant to the content of this report.
- 7.Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Advances Perit Dial 1993; 9: 187–9Google Scholar
- 9.Gloria del Peso M, Auxiliadora Bajo, Fernando G, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19: 32–5Google Scholar
- 10.Eltoum MA, Wright S, Atchley J, et al. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006; 26(2): 183–4Google Scholar
- 15.Kegg S, Lau R. Tamoxifen in antiretroviral-associated gynaecomastia. Int J STD AIDS 2002; 13(8): 582–3Google Scholar